Feature | Heart Valve Technology | March 14, 2017

Conscious Sedation TAVR Reduced Length-of-Stay and Hospital Costs

Minneapolis Heart Institute Foundation quality improvement review reduced LOS and cost without affecting the safety and outcomes of the procedure

TAVR, TAVI, conscience sedation

March 14, 2017 — Transcatheter aortic valve replacement (TAVR) for aortic stenosis continues to evolve with the adoption of methods intended to maximize efficacy, safety and patient recovery. Researchers at the Valve Science Center at Minneapolis Heart Institute Foundation recently conducted quality improvement review to examine the impact of the use of minimal anesthesia with conscious sedation (CS) in patients with severe, symptomatic aortic stenosis (AS) undergoing TAVR.
 
Using a multidisciplinary collaboration, a program was initiated to perform transfemoral TAVR with CS to treat patients with native valve AS.  Clinical outcomes for the first 50 patients treated with CS were compared to 50 control patients who had undergone TAVR with general anesthesia (GA) immediately preceding CS implementation. The two patient groups were similar with respect to age, hemodynamic severity of AS, symptom status and frailty. However, in comparison to GA patients, those who had TAVR with CS had shorter median procedure time and hospital length-of-stay (LOS). Procedural success with TAVR and major adverse complications were similar between the groups.  Overall, implementation of TAVR with CS led to a $2,833 reduction in median total variable costs per treated patient. Researchers concluded the implementation of a multidisciplinary program that enabled TAVR to be performed with CS led to significant reductions in LOS and hospital costs, without affecting the effectiveness and safety of the procedure.
 
“The evidence and insight gathered in this analysis supports a novel shift in how we manage our transfemoral TAVR patient population going forward,”  said Marcus Burns, DNP, principal investigator at the Minneapolis Heart Institute Foundation. “Conscious sedation, with its ability to maximize the ease of recovery from TAVR procedures, is a huge advancement for the many patients afflicted with aortic stenosis who seek treatment at our facility."  To date, researchers at the Valve Science Center at Minneapolis Heart Institute Foundation have performed more than 120 conscious sedation TF-TAVR’s since February 2016. “While interest in using conscious sedation for TAVR is steadily growing and a majority of centers have not yet adopted or just are beginning to adopt this approach in its true form," Burns explained.
 
The researchers will present their results at the American College of Cardiology (ACC) annual scientific session and expo this month.

 

Related Content for Conscious Sedadtion and TAVR:

VIDEO: Conscious Sedation for TAVR Procedures

Moderate Sedation Shows Promise for TAVR Patients

VIDEO: The State of TAVR in 2016

Michigan Hospital Employing Conscious Sedation for Aortic Aneurysm Repair

Moderate Sedation Shows Promise for TAVR Patients

UTHealth, Memorial Hermann Perform Conscious Sedation TAVR Procedure

 

 

Related Content

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broa
Overlay Init